Assessment of multiple-opinion referrals and consults at the BC Children’s Hospital Allergy Clinic

• Research
• Open Access
• 
  

• Adam P. Sage, 
• Elliot James, 
• Megan Burke, 
• Edmond S. Chan & 
• Tiffany Wong 

Allergy, Asthma & Clinical Immunology volume 19, Article number: 52 (2023) 

• details

Abstract

Background

Allergic disease is on the rise. Waitlists for specialists are long, and many referred patients have already received prior allergic assessment, either by a certified Allergist, Primary Care Provider, or other Specialist. It is important to understand the prevalence and motivating factors for multiple-opinion referrals, to deliver timely assessment for patients with allergic disease.

Methods

Assessment of the first presentations of common variable immunodeficiency in a large cohort of patients

• Research
• Open Access
• 
  

• Hossein Esmaeilzadeh, 
• Armita Jokar-Derisi, 
• Amir Hossein Hassani, 
• Reza Yazdani, 
• Samaneh Delavari, 
• Hassan Abolhassani, 
• Negar Mortazavi & 
• Aida Askarisarvestani 

BMC Immunology volume 24, Article number: 9 (2023) 

• details

Abstract

Background

Common Variable Immunodeficiency (CVID) is a primary immunodeficiency syndrome resulting in recurrent infections, autoimmunity, and granulomatous manifestations.

Methods and materials

This retrospective study was conducted on an Iranian national registry of immunodeficient patients from 2010 to 2021. The frequency of first presentations of CVID and its association with sex, age of onset, and family history of CVID was evaluated.

New EAACI Knowledge Hub Module: Drug Hypersensitivity Module

 

 

We encourage you to discover our newest EAACI Knowledge Hub content: “Drug Hypersensitivity Module"

The aim of the module is to provide information about basic and recent advancements in diagnosis and management of hypersensitivity reactions due to biologicals in order to harmonize the clinical approach among clinicians and enhance their information by looking at the topic from different angles.

Now available on the EAACI Knowledge Hub: NEW Allergen Immunotherapy Module

We are pleased to announce that the second Allergen Immunotherapy (AIT) module, dedicated to the latest advances, is now published!

This module focuses on the potential economic benefits of AIT, both for the patient and the society. It sheds light on the role of how eHealth technologies can support AIT's prescription, administration and monitoring. This module also provides novel insights into real world evidence (RWE) in AIT and their implications.

Mechanisms of Allergen Immunotherapy and Potential Biomarkers for Clinical Evaluation

Sahiner UM, Giovannini M, Escribese MM et al. J Pers Med. 2023 May 17;13(5):845. doi: 10.3390/jpm13050845. 

Abstract
Allergen-immunotherapy (AIT) is an efficacious and disease-modifying treatment option for IgE-mediated diseases. Among these allergic rhinitis, insect venom allergy, food allergy, and allergic asthma are the most common candidates for AIT.

AIT gives rise to clinical immunotolerance which may last for years after the treatment cessation. Mechanisms of AIT include suppression of allergic inflammation in target tissues and stimulation of the production of blocking antibodies, especially IgG4 and IgA. These mechanisms are followed by a reduction of underlying allergen-specific Th2 cell-driven responses to the allergens. Tolerance induction takes place through the desensitization of effector cells and stimulation of regulatory T cells that show their effects by mechanisms involving cell-cell cross-talk, but also other mechanisms, e.g., by the production of immunomodulatory cytokines such as, e.g., IL-10 and TGF-beta. From a personalized medical perspective, there is a need for clinical biomarkers of value in selecting responders and optimizing patient care during AIT.

EAACI guidelines on environmental science in allergic diseases and asthma – Leveraging artificial intelligence and machine learning to develop a causality model in exposomics

Shamji, MH, Ollert, M, Adcock, IM, et al. Allergy. 2023; 00: 1- 16. doi:10.1111/all.15667

Abstract

Allergic diseases and asthma are intrinsically linked to the environment we live in and to patterns of exposure. The integrated approach to understanding the effects of exposures on the immune system includes the ongoing collection of large-scale and complex data. This requires sophisticated methods to take full advantage of what this data can offer. Here we discuss the progress and further promise of applying artificial intelligence and machine-learning approaches to help unlock the power of complex environmental data sets toward providing causality models of exposure and intervention.

Assessment of autoantibodies in paediatric population with primary immunodeficiencies: a pilot study

• Research
• Open Access
• 
  

• Karolina Pieniawska-Śmiech, 
• Aleksandra Lewandowicz-Uszyńska, 
• Magdalena Zemelka-Wiacek & 
• Marek Jutel 

BMC Immunology volume 24, Article number: 8 (2023) 

• details

Abstract

Background

The correlation between primary immunodeficiencies (PIDs) and autoimmunity shows ethnic and geographical diversity. The aim of our study was to accumulate more data in paediatric PID population.

Methods

58 children aged 1–17 and with PID (study group) and 14 age-matched immunocompetent individuals (control group) were included in the study.

Extrapolating Evidence-Based Medicine of AIT Into Clinical Practice in the United States

Calderon MA, Casale TB, Nelson HS et al. J Allergy Clin Immunol Pract. 2023 Apr;11(4):1100-1115. doi: 10.1016/j.jaip.2022.10.033.

Executive Summary

This review sought to critically assess evidence-based medicine (EBM) for debated concepts in US allergy immunotherapy (AIT) practice for respiratory allergies in the context and quality of today’s regulatory standards. In addition, EBM for patient-centered AIT issues and the approach to implementation of AIT EBM in future clinical practice were addressed. The EBM for each concept was briefly summarized, and when possible, a practical, concise recommendation was given.

EBM in debated concepts for AIT: Individuals of all ages can have allergic rhinoconjunctivitis (ARC) and may have multiple allergen sensitivities or comorbid atopic conditions (eg, asthma).